KPV
Lysine-Proline-Valine
KPV is typically discussed for inflammatory and gut support, but it remains a restricted compounding ingredient today.
Current status
Restricted
Inflammation- and GI-related interest, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
Often considered a second-wave peptide that could benefit if FDA policy softens broadly.
Primary Use
Inflammation- and GI-related interest
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 29, 2023
Current status signal recorded: Remains in the restricted class for routine compounding..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when KPV status changes
State-specific notes
California
Generally unavailable from compliant in-state sources.